ES2906827T3 - Sistema multicomponente modificado por ingeniería para la identificación y caracterización de receptores de linfocitos T y antígenos de linfocitos T - Google Patents

Sistema multicomponente modificado por ingeniería para la identificación y caracterización de receptores de linfocitos T y antígenos de linfocitos T Download PDF

Info

Publication number: ES2906827T3
Authority: ES; Spain
Prior art keywords: eapc; component; aam; aapx; analyte
Prior art date: 2016-11-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES17800759T

Other languages

English (en)

Spanish (es)

Inventor

Reagan Micheal Jarvis

Ryan Edward Hill

Luke Benjamin Pase

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genovie AB

Original Assignee

Genovie AB

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-11-07

Filing date

2017-11-07

Publication date

2022-04-20

2017-11-07 Application filed by Genovie AB filed Critical Genovie AB

2022-04-20 Application granted granted Critical

2022-04-20 Publication of ES2906827T3 publication Critical patent/ES2906827T3/es

Status Active legal-status Critical Current

2037-11-07 Anticipated expiration legal-status Critical

Links

239000012491 analyte Substances 0.000 claims abstract description 513
239000000427 antigen Substances 0.000 claims abstract description 217
108091007433 antigens Proteins 0.000 claims abstract description 212
102000036639 antigens Human genes 0.000 claims abstract description 212
230000010354 integration Effects 0.000 claims abstract description 200
239000013598 vector Substances 0.000 claims abstract description 161
230000014509 gene expression Effects 0.000 claims abstract description 100
230000002068 genetic effect Effects 0.000 claims abstract description 86
102000018120 Recombinases Human genes 0.000 claims abstract description 38
108010091086 Recombinases Proteins 0.000 claims abstract description 38
210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 30
230000000890 antigenic effect Effects 0.000 claims abstract description 21
230000001404 mediated effect Effects 0.000 claims abstract description 13
210000004027 cell Anatomy 0.000 claims description 572
210000001744 T-lymphocyte Anatomy 0.000 claims description 138
108020003175 receptors Proteins 0.000 claims description 125
108090000765 processed proteins & peptides Proteins 0.000 claims description 119
238000000034 method Methods 0.000 claims description 94
108090000623 proteins and genes Proteins 0.000 claims description 76
230000004044 response Effects 0.000 claims description 58
239000003550 marker Substances 0.000 claims description 52
102000004196 processed proteins & peptides Human genes 0.000 claims description 42
238000012512 characterization method Methods 0.000 claims description 20
229920001184 polypeptide Polymers 0.000 claims description 18
108091035707 Consensus sequence Proteins 0.000 claims description 11
230000003612 virological effect Effects 0.000 claims description 11
239000002207 metabolite Substances 0.000 claims description 10
101100161407 Rhodococcus erythropolis aam gene Proteins 0.000 claims description 8
108010026552 Proteome Proteins 0.000 claims description 7
108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 6
230000001580 bacterial effect Effects 0.000 claims description 5
238000010367 cloning Methods 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
230000010076 replication Effects 0.000 claims description 5
239000003242 anti bacterial agent Substances 0.000 claims description 4
230000003115 biocidal effect Effects 0.000 claims description 4
108020005067 RNA Splice Sites Proteins 0.000 claims description 3
230000001105 regulatory effect Effects 0.000 claims description 3
230000004075 alteration Effects 0.000 claims description 2
108091008874 T cell receptors Proteins 0.000 description 232
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 180
102000005962 receptors Human genes 0.000 description 115
239000003153 chemical reaction reagent Substances 0.000 description 62
239000005090 green fluorescent protein Substances 0.000 description 60
230000009258 tissue cross reactivity Effects 0.000 description 52
108700026244 Open Reading Frames Proteins 0.000 description 50
101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 description 49
102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 description 49
108091005948 blue fluorescent proteins Proteins 0.000 description 49
108010043121 Green Fluorescent Proteins Proteins 0.000 description 46
102000004144 Green Fluorescent Proteins Human genes 0.000 description 46
102210042925 HLA-A*02:01 Human genes 0.000 description 39
108020004414 DNA Proteins 0.000 description 33
102000004169 proteins and genes Human genes 0.000 description 33
108091093088 Amplicon Proteins 0.000 description 32
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 32
238000003752 polymerase chain reaction Methods 0.000 description 32
239000013612 plasmid Substances 0.000 description 31
238000000684 flow cytometry Methods 0.000 description 28
108700028369 Alleles Proteins 0.000 description 27
238000010186 staining Methods 0.000 description 27
102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 26
102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 25
206010028980 Neoplasm Diseases 0.000 description 24
108010054624 red fluorescent protein Proteins 0.000 description 24
108010058607 HLA-B Antigens Proteins 0.000 description 23
108010075704 HLA-A Antigens Proteins 0.000 description 22
238000004520 electroporation Methods 0.000 description 22
238000004458 analytical method Methods 0.000 description 21
108020005004 Guide RNA Proteins 0.000 description 20
208000012868 Overgrowth Diseases 0.000 description 19
238000013459 approach Methods 0.000 description 18
230000015572 biosynthetic process Effects 0.000 description 18
108010058597 HLA-DR Antigens Proteins 0.000 description 17
102000006354 HLA-DR Antigens Human genes 0.000 description 17
238000006243 chemical reaction Methods 0.000 description 17
238000002360 preparation method Methods 0.000 description 17
230000008685 targeting Effects 0.000 description 17
230000008569 process Effects 0.000 description 16
230000006798 recombination Effects 0.000 description 16
238000005215 recombination Methods 0.000 description 16
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
239000002609 medium Substances 0.000 description 15
239000000203 mixture Substances 0.000 description 15
239000000047 product Substances 0.000 description 15
239000000523 sample Substances 0.000 description 15
230000002459 sustained effect Effects 0.000 description 15
201000011510 cancer Diseases 0.000 description 14
238000005516 engineering process Methods 0.000 description 14
108010052199 HLA-C Antigens Proteins 0.000 description 13
238000002372 labelling Methods 0.000 description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
230000001413 cellular effect Effects 0.000 description 12
230000001472 cytotoxic effect Effects 0.000 description 12
238000001514 detection method Methods 0.000 description 12
230000001225 therapeutic effect Effects 0.000 description 12
238000001890 transfection Methods 0.000 description 12
210000004698 lymphocyte Anatomy 0.000 description 11
239000000463 material Substances 0.000 description 11
244000052769 pathogen Species 0.000 description 11
102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 10
108010021727 HLA-A*24:02 antigen Proteins 0.000 description 10
241000701024 Human betaherpesvirus 5 Species 0.000 description 10
230000003993 interaction Effects 0.000 description 10
210000004986 primary T-cell Anatomy 0.000 description 10
108091033409 CRISPR Proteins 0.000 description 9
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
238000001943 fluorescence-activated cell sorting Methods 0.000 description 9
239000012071 phase Substances 0.000 description 9
239000002953 phosphate buffered saline Substances 0.000 description 9
238000012163 sequencing technique Methods 0.000 description 9
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 8
108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 8
102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 description 8
108010067802 HLA-DR alpha-Chains Proteins 0.000 description 8
108010039343 HLA-DRB1 Chains Proteins 0.000 description 8
239000000872 buffer Substances 0.000 description 8
238000003501 co-culture Methods 0.000 description 8
230000006870 function Effects 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
238000011068 loading method Methods 0.000 description 8
230000011664 signaling Effects 0.000 description 8
239000002904 solvent Substances 0.000 description 8
102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 7
230000008878 coupling Effects 0.000 description 7
238000010168 coupling process Methods 0.000 description 7
238000005859 coupling reaction Methods 0.000 description 7
230000035772 mutation Effects 0.000 description 7
239000002245 particle Substances 0.000 description 7
230000009897 systematic effect Effects 0.000 description 7
OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 6
229930186217 Glycolipid Natural products 0.000 description 6
102100031618 HLA class II histocompatibility antigen, DP beta 1 chain Human genes 0.000 description 6
108010045483 HLA-DPB1 antigen Proteins 0.000 description 6
238000012790 confirmation Methods 0.000 description 6
238000012217 deletion Methods 0.000 description 6
230000037430 deletion Effects 0.000 description 6
238000011161 development Methods 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
230000008488 polyadenylation Effects 0.000 description 6
238000012545 processing Methods 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
230000002992 thymic effect Effects 0.000 description 6
HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 5
108090000672 Annexin A5 Proteins 0.000 description 5
102000004121 Annexin A5 Human genes 0.000 description 5
108010019670 Chimeric Antigen Receptors Proteins 0.000 description 5
102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 5
108010093061 HLA-DPA1 antigen Proteins 0.000 description 5
108091028043 Nucleic acid sequence Proteins 0.000 description 5
239000012980 RPMI-1640 medium Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
102000054766 genetic haplotypes Human genes 0.000 description 5
230000004941 influx Effects 0.000 description 5
150000002632 lipids Chemical class 0.000 description 5
238000004949 mass spectrometry Methods 0.000 description 5
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
238000005070 sampling Methods 0.000 description 5
238000002741 site-directed mutagenesis Methods 0.000 description 5
230000010473 stable expression Effects 0.000 description 5
101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 description 4
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 4
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 4
102400001018 Proadrenomedullin N-20 terminal peptide Human genes 0.000 description 4
101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 4
108091081024 Start codon Proteins 0.000 description 4
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 4
208000026487 Triploidy Diseases 0.000 description 4
230000033289 adaptive immune response Effects 0.000 description 4
230000004721 adaptive immunity Effects 0.000 description 4
239000011543 agarose gel Substances 0.000 description 4
239000002543 antimycotic Substances 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000005784 autoimmunity Effects 0.000 description 4
230000009260 cross reactivity Effects 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000003814 drug Substances 0.000 description 4
239000012634 fragment Substances 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
238000002955 isolation Methods 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
239000012474 protein marker Substances 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
238000012546 transfer Methods 0.000 description 4
BLCYCYHFLMGVPO-UHFFFAOYSA-N 2-(1h-benzimidazole-2-carbonyl)-3h-benzimidazole-5-carboximidamide Chemical compound C1=CC=C2NC(C(=O)C3=NC4=CC=C(C=C4N3)C(=N)N)=NC2=C1 BLCYCYHFLMGVPO-UHFFFAOYSA-N 0.000 description 3
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
238000010354 CRISPR gene editing Methods 0.000 description 3
108010047041 Complementarity Determining Regions Proteins 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
102100036243 HLA class II histocompatibility antigen, DQ alpha 1 chain Human genes 0.000 description 3
101150118346 HLA-A gene Proteins 0.000 description 3
101150000578 HLA-B gene Proteins 0.000 description 3
101150035071 HLA-C gene Proteins 0.000 description 3
108010086786 HLA-DQA1 antigen Proteins 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
108060003951 Immunoglobulin Proteins 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
102000000440 Melanoma-associated antigen Human genes 0.000 description 3
108050008953 Melanoma-associated antigen Proteins 0.000 description 3
101710163270 Nuclease Proteins 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
101150069122 aam gene Proteins 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000003044 adaptive effect Effects 0.000 description 3
208000026935 allergic disease Diseases 0.000 description 3
230000007815 allergy Effects 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
230000011748 cell maturation Effects 0.000 description 3
230000009918 complex formation Effects 0.000 description 3
238000010276 construction Methods 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
238000000605 extraction Methods 0.000 description 3
235000019253 formic acid Nutrition 0.000 description 3
238000007429 general method Methods 0.000 description 3
230000012010 growth Effects 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000036039 immunity Effects 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
238000009169 immunotherapy Methods 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
239000003446 ligand Substances 0.000 description 3
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
239000006166 lysate Substances 0.000 description 3
230000036210 malignancy Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
238000003032 molecular docking Methods 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
238000012216 screening Methods 0.000 description 3
241000894007 species Species 0.000 description 3
238000012360 testing method Methods 0.000 description 3
210000001541 thymus gland Anatomy 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
241001515965 unidentified phage Species 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
239000012099 Alexa Fluor family Substances 0.000 description 2
102000000412 Annexin Human genes 0.000 description 2
108050008874 Annexin Proteins 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
208000009329 Graft vs Host Disease Diseases 0.000 description 2
102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 description 2
108010041384 HLA-DPA antigen Proteins 0.000 description 2
108010067148 HLA-DQbeta antigen Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000981375 Homo sapiens Nuclear cap-binding protein subunit 1 Proteins 0.000 description 2
101150008942 J gene Proteins 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
108700005089 MHC Class I Genes Proteins 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
102100024372 Nuclear cap-binding protein subunit 1 Human genes 0.000 description 2
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
206010052779 Transplant rejections Diseases 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
101150117115 V gene Proteins 0.000 description 2
230000009824 affinity maturation Effects 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
230000030741 antigen processing and presentation Effects 0.000 description 2
230000002457 bidirectional effect Effects 0.000 description 2
229910002056 binary alloy Inorganic materials 0.000 description 2
210000004970 cd4 cell Anatomy 0.000 description 2
230000022534 cell killing Effects 0.000 description 2
238000002659 cell therapy Methods 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000004891 communication Methods 0.000 description 2
239000000470 constituent Substances 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
230000002559 cytogenic effect Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
238000012350 deep sequencing Methods 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
210000004443 dendritic cell Anatomy 0.000 description 2
230000001066 destructive effect Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
229940088679 drug related substance Drugs 0.000 description 2
239000012997 ficoll-paque Substances 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
102000034287 fluorescent proteins Human genes 0.000 description 2
108091006047 fluorescent proteins Proteins 0.000 description 2
235000013305 food Nutrition 0.000 description 2
238000010230 functional analysis Methods 0.000 description 2
230000004927 fusion Effects 0.000 description 2
238000010362 genome editing Methods 0.000 description 2
210000004602 germ cell Anatomy 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
208000024908 graft versus host disease Diseases 0.000 description 2
230000036541 health Effects 0.000 description 2
230000037451 immune surveillance Effects 0.000 description 2
210000000428 immunological synapse Anatomy 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
239000007791 liquid phase Substances 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
239000003471 mutagenic agent Substances 0.000 description 2
231100000707 mutagenic chemical Toxicity 0.000 description 2
230000003505 mutagenic effect Effects 0.000 description 2
239000013642 negative control Substances 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
210000004287 null lymphocyte Anatomy 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
230000007170 pathology Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
238000002823 phage display Methods 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
230000037452 priming Effects 0.000 description 2
230000010349 pulsation Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000000284 resting effect Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000000392 somatic effect Effects 0.000 description 2
238000004611 spectroscopical analysis Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
230000010474 transient expression Effects 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
238000001195 ultra high performance liquid chromatography Methods 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
239000011534 wash buffer Substances 0.000 description 2
101150084750 1 gene Proteins 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
HUVSHHCYCJKXBZ-UHFFFAOYSA-N 2,3-bis(ethenyl)benzenesulfonic acid;styrene Chemical compound C=CC1=CC=CC=C1.OS(=O)(=O)C1=CC=CC(C=C)=C1C=C HUVSHHCYCJKXBZ-UHFFFAOYSA-N 0.000 description 1
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
101150096316 5 gene Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010031480 Artificial Receptors Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
102000049320 CD36 Human genes 0.000 description 1
108010045374 CD36 Antigens Proteins 0.000 description 1
102000041075 Class I family Human genes 0.000 description 1
108091060777 Class I family Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
108010002947 Connectin Proteins 0.000 description 1
101150097493 D gene Proteins 0.000 description 1
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
102210048109 DRB1*01:01 Human genes 0.000 description 1
AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical class CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
102100027285 Fanconi anemia group B protein Human genes 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
102000002068 Glycopeptides Human genes 0.000 description 1
108010015899 Glycopeptides Proteins 0.000 description 1
241000251728 Gnathostomata <vertebrate> Species 0.000 description 1
102000025850 HLA-A2 Antigen Human genes 0.000 description 1
108010074032 HLA-A2 Antigen Proteins 0.000 description 1
108010010378 HLA-DP Antigens Proteins 0.000 description 1
102000015789 HLA-DP Antigens Human genes 0.000 description 1
108010065026 HLA-DQB1 antigen Proteins 0.000 description 1
-1 HLA-DRB Proteins 0.000 description 1
101000914679 Homo sapiens Fanconi anemia group B protein Proteins 0.000 description 1
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
101000772138 Homo sapiens T cell receptor alpha variable 1-2 Proteins 0.000 description 1
101000738335 Homo sapiens T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 description 1
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
108010028921 Lipopeptides Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
101100405118 Mus musculus Nr4a1 gene Proteins 0.000 description 1
101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
102000012064 NLR Proteins Human genes 0.000 description 1
108091005686 NOD-like receptors Proteins 0.000 description 1
102100022679 Nuclear receptor subfamily 4 group A member 1 Human genes 0.000 description 1
239000012807 PCR reagent Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
206010036618 Premenstrual syndrome Diseases 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
102100029308 T cell receptor alpha variable 1-2 Human genes 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
102100037906 T-cell surface glycoprotein CD3 zeta chain Human genes 0.000 description 1
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
102000000591 Tight Junction Proteins Human genes 0.000 description 1
108010002321 Tight Junction Proteins Proteins 0.000 description 1
102100026260 Titin Human genes 0.000 description 1
102000002689 Toll-like receptor Human genes 0.000 description 1
108020000411 Toll-like receptor Proteins 0.000 description 1
101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
101100405120 Xenopus laevis nr4a1 gene Proteins 0.000 description 1
108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
210000005006 adaptive immune system Anatomy 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
229940124691 antibody therapeutics Drugs 0.000 description 1
230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
AEIMYPLMACPBOD-UHFFFAOYSA-N carbonocyanidic acid;nickel Chemical compound [Ni].OC(=O)C#N AEIMYPLMACPBOD-UHFFFAOYSA-N 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
239000002771 cell marker Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000010267 cellular communication Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
230000004637 cellular stress Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
108700010039 chimeric receptor Proteins 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
238000005094 computer simulation Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
210000005220 cytoplasmic tail Anatomy 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000002074 deregulated effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000012149 elution buffer Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000010195 expression analysis Methods 0.000 description 1
238000009313 farming Methods 0.000 description 1
238000010265 fast atom bombardment Methods 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
238000012224 gene deletion Methods 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
238000003205 genotyping method Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000012145 high-salt buffer Substances 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
244000052637 human pathogen Species 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000008073 immune recognition Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
230000035992 intercellular communication Effects 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
108010028930 invariant chain Proteins 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000009126 molecular therapy Methods 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000000581 natural killer T-cell Anatomy 0.000 description 1
238000007481 next generation sequencing Methods 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
108010089193 pattern recognition receptors Proteins 0.000 description 1
102000007863 pattern recognition receptors Human genes 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000003836 peripheral circulation Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
208000031223 plasma cell leukemia Diseases 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
229940021993 prophylactic vaccine Drugs 0.000 description 1
238000002818 protein evolution Methods 0.000 description 1
238000004725 rapid separation liquid chromatography Methods 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
229960002477 riboflavin Drugs 0.000 description 1
235000019192 riboflavin Nutrition 0.000 description 1
239000002151 riboflavin Substances 0.000 description 1
238000010187 selection method Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000012192 staining solution Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000004885 tandem mass spectrometry Methods 0.000 description 1
229940021747 therapeutic vaccine Drugs 0.000 description 1
210000001578 tight junction Anatomy 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
239000012096 transfection reagent Substances 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
238000011282 treatment Methods 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
- C12N2310/153—Nucleic acids forming more than 2 strands, e.g. TFOs with the aid of a protein, e.g. recombinase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/10—Vectors comprising a non-peptidic targeting moiety

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Hematology (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Mycology (AREA)
Veterinary Medicine (AREA)
Toxicology (AREA)
Developmental Biology & Embryology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Urology & Nephrology (AREA)
Tropical Medicine & Parasitology (AREA)
Crystallography & Structural Chemistry (AREA)
Bioinformatics & Computational Biology (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)

ES17800759T 2016-11-07 2017-11-07 Sistema multicomponente modificado por ingeniería para la identificación y caracterización de receptores de linfocitos T y antígenos de linfocitos T Active ES2906827T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA201670872		2016-11-07
PCT/EP2017/078376 WO2018083316A1 (fr)	2016-11-07	2017-11-07	Système à composants multiples génétiquement modifiés pour l'identification et la caractérisation de récepteurs de lymphocytes t et d'antigènes de lymphocytes t

Publications (1)

Publication Number	Publication Date
ES2906827T3 true ES2906827T3 (es)	2022-04-20

Family

ID=57460292

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
ES17800759T Active ES2906827T3 (es)	2016-11-07	2017-11-07	Sistema multicomponente modificado por ingeniería para la identificación y caracterización de receptores de linfocitos T y antígenos de linfocitos T
ES22150892T Active ES2968633T3 (es)	2016-11-07	2017-11-07	Sistema multicomponente modificado por ingeniería para la identificación y caracterización de receptores de linfocitos T y antígenos de linfocitos T
ES22150893T Active ES3034256T3 (en)	2016-11-07	2017-11-07	An engineered multi-component system used for selecting t-cell receptors, t-cells and engineered antigen presenting cells.

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
ES22150892T Active ES2968633T3 (es)	2016-11-07	2017-11-07	Sistema multicomponente modificado por ingeniería para la identificación y caracterización de receptores de linfocitos T y antígenos de linfocitos T
ES22150893T Active ES3034256T3 (en)	2016-11-07	2017-11-07	An engineered multi-component system used for selecting t-cell receptors, t-cells and engineered antigen presenting cells.

Country Status (12)

Country	Link
US (3)	US12012610B2 (fr)
EP (4)	EP4332232A3 (fr)
JP (3)	JP7645606B2 (fr)
KR (3)	KR102833088B1 (fr)
CN (3)	CN118909953A (fr)
AU (2)	AU2017352589B2 (fr)
CA (1)	CA3038917A1 (fr)
DK (2)	DK4039800T5 (fr)
ES (3)	ES2906827T3 (fr)
FI (1)	FI4039800T3 (fr)
NZ (2)	NZ794207A (fr)
WO (1)	WO2018083316A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP4332232A3 (fr)	2016-11-07	2024-05-08	Genovie AB	Système à composants multiples modifié pour l'identification et la caractérisation de récepteurs de lymphocytes t et d'antigènes de lymphocytes t
EP3535393B1 (fr)	2016-11-07	2021-09-22	Genovie AB	Système de bibliothèque de vecteurs à deux composants pour assemblage rapide et diversification de cadres de lecture ouverts du récepteur des lymphocytes t pleine longueur
CN112513279B (zh) *	2018-07-09	2025-01-17	杰诺维有限公司	用于在重组酶介导的核酸序列向工程化的接受细胞发生盒交换整合期间追踪和操纵细胞的细胞表面标签交换(cste)系统
WO2021219619A1 (fr)	2020-04-27	2021-11-04	Genovie Ab	Procédés pour générer des compositions de vaccin qui amorce des réponses de lymphocytes t cd8 restreints par un antigène leucocytaire humain de classe i contre des épitopes dérivés intrinsèques non virion
EP4570263A1 (fr)	2023-12-15	2025-06-18	Genovie AB	Tcr reconnaissant ras muté g12v et leurs utilisations
WO2025125590A2 (fr)	2023-12-15	2025-06-19	Genovie Ab	Tcr reconnaissant le ras à mutation g12v et leurs utilisations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003065977A2 (fr)	2001-11-20	2003-08-14	Dana-Farber Cancer Institute	Cellules presentatrices d'antigene modifiees
US20100291633A1 (en)	2007-09-03	2010-11-18	Thorsten Selmer	Method of cloning at least one nucleic acid molecule of interest using type iis restriction endonucleases, and corresponding cloning vectors, kits and system using type iis restriction endonucleases
EP2395087A1 (fr)	2010-06-11	2011-12-14	Icon Genetics GmbH	Système et procédé de clonage modulaire
EP2601521B1 (fr)	2010-08-06	2018-05-02	Ludwig-Maximilians-Universität München	Identification d'antigènes cibles de lymphocytes t
WO2013144257A1 (fr)	2012-03-27	2013-10-03	Dsm Ip Assets B.V.	Procédé de clonage
JP6126804B2 (ja)	2012-07-25	2017-05-10	国立大学法人富山大学	Ｔ細胞受容体のクローニング方法
AU2014235968B2 (en)	2013-03-21	2018-05-24	Ospedale San Raffaele Srl	Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
ES2740930T3 (es)	2014-03-14	2020-02-07	Immunocore Ltd	Bibliotecas de TCR
KR20160145186A (ko)	2014-04-24	2016-12-19	보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템	입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
GB201407852D0 (en) *	2014-05-02	2014-06-18	Iontas Ltd	Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
KR102546296B1 (ko)	2014-10-31	2023-06-21	더 트러스티스 오브 더 유니버시티 오브 펜실베니아	변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
CA2964785A1 (fr) *	2014-11-05	2016-05-12	Board Of Regents, The University Of Texas System	Cellules immunitaires effectrices genetiquement modifiees et cellules manipulees pour l'expansion de cellules immunitaires effectrices
DK3271382T3 (da)	2015-03-16	2020-05-04	Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft	Fremgangsmåde til detektion af nye immunogene T-celleepitoper og isolering af nye antigenspecifikke T-cellereceptorer ved hjælp af et MHC-cellebibliotek
AU2016273213B2 (en)	2015-06-01	2019-03-14	Medigene Immunotherapies Gmbh	T cell receptor library
CN105316362B (zh) *	2015-08-19	2020-03-17	暨南大学	一种Dual-RMCE介导的TCR基因置换系统及其方法
EP4332232A3 (fr)	2016-11-07	2024-05-08	Genovie AB	Système à composants multiples modifié pour l'identification et la caractérisation de récepteurs de lymphocytes t et d'antigènes de lymphocytes t
KR102606929B1 (ko)	2016-11-07	2023-11-27	제노비에 에이비	동족 항원과 t-세포 수용체 상호작용의 발견 및 특징규명을 위한 조작된 2-부분 세포 디바이스
US20200095574A1 (en)	2016-11-07	2020-03-26	Genovie Ab	An engineered multi-component system for identification and characterisation of t-cell receptors, t-cell antigens and their functional interaction
EP3535393B1 (fr)	2016-11-07	2021-09-22	Genovie AB	Système de bibliothèque de vecteurs à deux composants pour assemblage rapide et diversification de cadres de lecture ouverts du récepteur des lymphocytes t pleine longueur
JP7335224B2 (ja)	2017-07-18	2023-08-29	ジェノヴィーエービー	全長ｔ細胞受容体オープンリーディングフレームの迅速な組立ておよび多様化のための二成分ベクターライブラリシステム

2017
- 2017-11-07 EP EP23205652.3A patent/EP4332232A3/fr not_active Withdrawn
- 2017-11-07 KR KR1020247001226A patent/KR102833088B1/ko active Active
- 2017-11-07 ES ES17800759T patent/ES2906827T3/es active Active
- 2017-11-07 ES ES22150892T patent/ES2968633T3/es active Active
- 2017-11-07 CN CN202411032683.9A patent/CN118909953A/zh active Pending
- 2017-11-07 CN CN202411032748.XA patent/CN118931845A/zh active Pending
- 2017-11-07 CN CN201780068369.8A patent/CN109923207B/zh active Active
- 2017-11-07 KR KR1020197013901A patent/KR102625785B1/ko active Active
- 2017-11-07 EP EP17800759.7A patent/EP3535387B1/fr active Active
- 2017-11-07 DK DK22150892.2T patent/DK4039800T5/da active
- 2017-11-07 AU AU2017352589A patent/AU2017352589B2/en active Active
- 2017-11-07 US US16/347,684 patent/US12012610B2/en active Active
- 2017-11-07 CA CA3038917A patent/CA3038917A1/fr active Pending
- 2017-11-07 EP EP22150893.0A patent/EP4019625B1/fr active Active
- 2017-11-07 NZ NZ794207A patent/NZ794207A/en unknown
- 2017-11-07 JP JP2019546059A patent/JP7645606B2/ja active Active
- 2017-11-07 KR KR1020247001227A patent/KR102956777B1/ko active Active
- 2017-11-07 EP EP22150892.2A patent/EP4039800B1/fr active Active
- 2017-11-07 DK DK17800759.7T patent/DK3535387T3/da active
- 2017-11-07 ES ES22150893T patent/ES3034256T3/es active Active
- 2017-11-07 WO PCT/EP2017/078376 patent/WO2018083316A1/fr not_active Ceased
- 2017-11-07 FI FIEP22150892.2T patent/FI4039800T3/fi active
- 2017-11-07 NZ NZ752629A patent/NZ752629A/en unknown
2020
- 2020-04-30 US US16/863,119 patent/US12270047B2/en active Active
2022
- 2022-12-02 JP JP2022193623A patent/JP7684271B2/ja active Active
2024
- 2024-07-22 AU AU2024205017A patent/AU2024205017A1/en active Pending
2025
- 2025-03-06 US US19/072,854 patent/US20250297211A1/en active Pending
- 2025-05-15 JP JP2025082058A patent/JP2025122051A/ja active Pending

Also Published As

Publication number	Publication date
ES3034256T3 (en)	2025-08-14
EP3535387A1 (fr)	2019-09-11
WO2018083316A1 (fr)	2018-05-11
KR20240010103A (ko)	2024-01-23
KR102833088B1 (ko)	2025-07-10
JP2019534047A (ja)	2019-11-28
AU2017352589A1 (en)	2019-05-16
KR20190076991A (ko)	2019-07-02
KR102956777B1 (ko)	2026-04-23
EP4019625A1 (fr)	2022-06-29
ES2968633T3 (es)	2024-05-13
JP2025122051A (ja)	2025-08-20
KR102625785B1 (ko)	2024-01-16
CN118909953A (zh)	2024-11-08
US20190359934A1 (en)	2019-11-28
JP7684271B2 (ja)	2025-05-27
NZ794207A (en)	2026-03-27
JP7645606B2 (ja)	2025-03-14
EP4039800A1 (fr)	2022-08-10
DK3535387T3 (da)	2022-02-14
EP4019625B1 (fr)	2025-04-02
CN109923207B (zh)	2024-08-16
DK4039800T3 (da)	2024-01-02
US20200339946A1 (en)	2020-10-29
US20250297211A1 (en)	2025-09-25
DK4039800T5 (da)	2024-07-29
EP4332232A2 (fr)	2024-03-06
CA3038917A1 (fr)	2018-05-11
JP2023025182A (ja)	2023-02-21
KR20240010545A (ko)	2024-01-23
EP3535387B1 (fr)	2022-01-12
US12012610B2 (en)	2024-06-18
NZ752629A (en)	2023-04-28
AU2017352589B2 (en)	2024-08-08
FI4039800T3 (fi)	2023-12-15
AU2024205017A1 (en)	2024-08-15
EP4039800B1 (fr)	2023-10-25
CN109923207A (zh)	2019-06-21
EP4332232A3 (fr)	2024-05-08
CN118931845A (zh)	2024-11-12
EP4019625C0 (fr)	2025-04-02
US12270047B2 (en)	2025-04-08

Publication	Publication Date	Title
ES2970535T3 (es)	2024-05-29	Dispositivo celular de dos partes modificado por ingeniería para el descubrimiento y la caracterización de una interacción de receptor de linfocitos T con antígeno relacionado
ES2984900T3 (es)	2024-10-31	Un sistema multicomponente modificado para la identificación y caracterización de receptores de células T, antígenos de células T y su interacción funcional
ES2968633T3 (es)	2024-05-13	Sistema multicomponente modificado por ingeniería para la identificación y caracterización de receptores de linfocitos T y antígenos de linfocitos T
ES2900151T3 (es)	2022-03-16	Un dispositivo de dos partes para la síntesis del receptor de linfocitos T0 e integración genómica estable en células presentadoras del TCR
ES2857052T3 (es)	2021-09-28	Receptores de antígenos quiméricos y métodos de uso
HK40078320A (en)	2023-03-31	An engineered multi-component system for identification and characterisation of t-cell receptors and t-cell antigens
HK40075973A (en)	2023-02-03	An engineered multi-component system used for selecting t-cell receptors, t-cells and engineered antigen presenting cells
HK40013512A (en)	2020-08-07	An engineered multi-component system for identification and characterisation of t-cell receptors and t-cell antigens
HK40013512B (en)	2022-05-20	An engineered multi-component system for identification and characterisation of t-cell receptors and t-cell antigens
NZ794221A (en)	2026-05-29	An Engineered Multi-component System for Identification and Characterisation of T-cell receptors,